Analyst Price Targets — COLL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 10, 2026 2:21 pm | Les Sulewski | Truist Financial | $58.00 | $46.21 | TheFly | Collegium Pharmaceutical price target raised to $58 from $55 at Truist |
| January 9, 2026 12:20 pm | — | Barclays | $56.00 | $48.78 | TheFly | Collegium price target lowered to $56 from $58 at Barclays |
| January 9, 2026 11:10 am | — | H.C. Wainwright | $60.00 | $48.78 | TheFly | Collegium Pharmaceutical price target raised to $60 from $46 at H.C. Wainwright |
| January 7, 2026 12:21 pm | — | Truist Financial | $55.00 | $46.21 | TheFly | Collegium Pharmaceutical price target raised to $55 from $47 at Truist |
| December 8, 2025 9:25 pm | — | Barclays | $58.00 | $47.91 | TheFly | Collegium Pharmaceutical initiated with an Overweight at Barclays |
| February 4, 2025 11:38 am | David Amsellem | Piper Sandler | $36.00 | $30.93 | TheFly | Collegium Pharmaceutical price target lowered to $36 from $37 at Piper Sandler |
| November 11, 2024 8:55 pm | Glen Santangelo | Jefferies | $40.00 | $32.18 | StreetInsider | Collegium Pharmaceutical (COLL) PT Lowered to $40 at Jefferies |
| September 4, 2024 12:25 pm | Oren Livnat | H.C. Wainwright | $50.00 | $38.65 | TheFly | Collegium Pharmaceutical price target raised to $50 from $47 at H.C. Wainwright |
| August 9, 2024 9:15 am | David Amsellem | Piper Sandler | $37.00 | $34.63 | StreetInsider | Collegium Pharmaceutical (COLL) PT Lowered to $37 at Piper Sandler |
| July 30, 2024 6:12 am | Oren Livnat | H.C. Wainwright | $47.00 | $38.60 | StreetInsider | H.C. Wainwright Upgrades Collegium Pharmaceutical (COLL) to Buy |
Latest News for COLL
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
COLL, IRWD, AMTB and DUK stand out as defensive stock picks as investors rotate from AI-driven tech amid the ongoing sell-off and seek safer sectors.
BBCP, KUBTY, ADM, COLL and W have been added to the Zacks Rank #1 (Strong Buy) List on July 6, 2026.
COLL gains momentum as strong Jornay PM growth and the Azstarys acquisition boosted 2026 guidance, strengthening its ADHD franchise and revenue outlook.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for COLL.
U.S. House Trading
No House trades found for COLL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.